头颈癌选择性颈部放疗降剂量:UPGRADE-RT 急性毒性二次分析
UPGRADE-RT 随机试验的急性毒性二次分析纳入 295 例口咽、喉或下咽鳞癌患者,比较选择性颈部照射 43 Gy 与 50 Gy。降剂量组咽黏膜上皮平均剂量≥45 Gy 者更少,且≥3 级吞咽困难(需管饲)显著减少。
要点
- 选择性颈部照射降剂量至 43 Gy 可减少咽黏膜上皮高剂量暴露。
- 降剂量组≥3 级吞咽困难(需管饲)风险显著低于标准剂量组。
- 咽黏膜上皮平均剂量≥45 Gy 与≥3 级黏膜炎和吞咽困难风险增加相关。
核心结论
- 选择性颈部照射降剂量使更多患者咽黏膜上皮平均剂量低于 45 Gy。
- 该降剂量与≥3 级咽黏膜炎和≥3 级急性吞咽困难(需管饲)发生率降低相关。
研究设计与样本
- 多中心随机对照 UPGRADE-RT 试验(NCT02442375)的急性毒性二次分析。
- 选择性颈部照射随机按 2:1 分配至降剂量组 43 Gy 或对照组 50 Gy。
- 急性毒性按 CTC v2.0 评分至放疗开始后 90 天,共 295 例可评估(降剂量组 196 例,对照组 99 例)。
主要发现
- 降剂量组≥3 级吞咽困难(需管饲)发生率显著低于对照组(RR 0.56,95%CI 0.32–0.98,p=0.046)。
- 咽黏膜上皮平均剂量≥45 Gy 与≥3 级黏膜炎风险增加相关(RR 1.41,95%CI 1.17–1.70,p<0.001)。
- 咽黏膜上皮平均剂量≥45 Gy 与≥3 级吞咽困难需管饲风险增加相关(RR 3.61,95%CI 1.72–7.57,p<0.001)。
- 降剂量组咽黏膜上皮平均剂量≥45 Gy 的患者比例更低(RR 0.80,95%CI 0.65–0.99,p=0.041)。
关键数值与推荐
- 选择性颈部照射降剂量组为 43 Gy,对照组为 50 Gy。
- 咽黏膜上皮平均剂量阈值 45 Gy 与≥3 级黏膜炎和吞咽困难风险相关。
临床怎么用
- 对头颈鳞癌根治性放疗患者,可考虑选择性颈部照射降剂量至 43 Gy 以减少急性吞咽困难和黏膜炎。
- 计划评估时关注咽黏膜上皮平均剂量,尽量控制在 45 Gy 以下以降低≥3 级急性毒性风险。
局限性
- 本文为急性毒性二次分析,非预设主要终点分析。
- 随访仅至放疗开始后 90 天,未报告晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multicenter, randomized UPGRADE-RT trial (NCT02442375) evaluated the safety and clinical benefit of elective neck radiotherapy with reduced versus standard dose in head and neck squamous cell carcinoma (SCC). This is a secondary analysis of acute toxicity. METHODS: Three hundred patients with cT2-4 N0-2 M0 SCC of the oropharynx, larynx or hypopharynx received definitive accelerated radiotherapy alone (34 fractions of 2 Gy in 5.5 weeks). Dose for elective neck irradiation was randomly assigned (ratio 2:1 to dose reduction, 43 Gy versus control, 50 Gy). Radiation induced acute toxicity was scored according to the CTC v2.0 until 90 days after start of radiotherapy. RESULTS: The analysis included 295 evaluable patients (dose reduction, 196 and control, 99). Dysphagia grade ≥ 3 (requiring tube feeding) occurred significantly less in the dose reduction group compared to controls (RR, 0.56, [95 % CI, 0.32 to 0.98], p = 0.046). A mean dose ≥ 45 Gy to the pharyngeal mucosal epithelium was associated with increased rates of mucositis grade ≥ 3 (RR, 1.41, [95 % CI, 1.17 to 1.70], p < 0.001) and dysphagia grade ≥ 3 requiring tube feeding (RR, 3.61, [95 % CI, 1.72 to 7.57], p < 0.001). Less patients in the dose reduction group had a pharyngeal mucosal epithelium mean dose ≥ 45 Gy (RR, 0.80, [95 % CI, 0.65 to 0.99], p = 0.041). CONCLUSION: Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy. This was associated with a reduced rate of grade ≥ 3 pharyngeal mucositis and a lower rate of acute dysphagia grade ≥ 3 (requiring tube feeding).
引用
- van den Bosch S, Cox MC, Doornaert PAH, et al. Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial. Radiother Oncol. 2025. PMID: 41057084. doi:10.1016/j.radonc.2025.111196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。